IPO filing research

Braveheart Bio, Inc.

Pharmaceutical Preparations

ipo amended Nasdaq S-1

Braveheart Bio, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-15. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common · Exchange Nasdaq · Ticker BRVE · Use of proceeds Proceeds will be used for general corporate purposes, including working capital and research and development · Underwriters Goldman Sachs & Co. LLC, Jefferies, TD Cowen

Braveheart Bio, Inc. is preparing for its IPO, focusing on the development of its lead product candidate, BHB-1893. The company relies heavily on third-party manufacturers, particularly Hengrui, for clinical and commercial supply, exposing it to significant supply chain risks. Intellectual property (IP) licensing challenges, including potential disputes and non-exclusive agreements, pose additional hurdles. Manufacturing scalability, regulatory compliance, and geopolitical disruptions further complicate its path to commercialization. The filing emphasizes risks related to IP rights, dependency on external partners, and the competitive landscape for third-party IP acquisition.

2026-07-15 · 0001628280-26-048213

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-06-08 · 0001628279-26-000717

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-04-29 · 0001628279-26-000549

Comparable Deals

16 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 16 using nearest neighbors.

Showing top 8 by similarity.

-1.3%

Median day-1

50%

Above issue

-1.3%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Aardvark Therapeutics, Inc. AARD

2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%

same SICrecent IPO

Recent News

No recent news stored for this issuer.